This large sector covers the production and sale of consumer goods, as well as various consumer services including electronic commerce and health care. Since 1996, Baring Vostok funds have invested over $400 million in 13 companies from this sector.
Location:
Saint Petersburg, Russia
Years:
2016
Shareholding:
Minority stake

Solopharm is a producer of pharmaceuticals, with focus on liquid drugs production. Product portfolio of Solopharm includes infusions, injectables, and a number of emerging branded products — ophthalmological drugs, nasal forms. All the drugs are generic drugs. Products are sold both to Russian hospitals and to pharmacies. The Company operates modern production facility located in Saint-Petersburg.

Other projects

News

24 November 2020

21 years later….

Letter from Baring Vostok Senior Partner Elena Ivashentseva to colleagues and friends in relation to Ozon’s IPO
19 November 2019

TJX acquires 25% of Familia.

A Baring Vostok portfolio company Familia – Russia’s leading off-price apparel and home fashions retailer – announced that the TJX Companies has acquired a 25% ownership stake in the Company from existing shareholders for USD 225 million.
11 November 2019

Media Statement.

Baring Vostok statement regarding the decision of the Moscow City Court to refuse changes to Ivan Zyuzin's and Vagan Abgaryan's pre-trial detention measures.
06 November 2019

Media Statement.

Baring Vostok statement regarding the decision of the Moscow City Court (Mosgorsud) to prolong the pre-trial detention of Maxim Vladimirov.